Exhibit 99.1

 

 

Helomics Holding Corporation

Consolidated Balance Sheet

	December 31st
	2018			2017
Current Assets:	(As Restated)			(As Restated)
Cash & cash equivalents	$	30,802		$	45,016
Accounts receivable - net		237,640			424,299
Inventories		17,508			40,279
Prepaid expenses		21,445			32,158
Total Current Assets		307,395			541,752
Fixed assets, net		1,203,572			2,398,844
Intangible, net		160,775			174,803
Equity investment		682,000			–
Total Assets	$	2,353,742		$	3,115,399
Current Liabilities:
Accounts payable	$	2,112,732		$	2,251,751
Accrued expenses		1,515,947			682,170
Capital leases - short term		5,258			85,840
Notes payable - Predictive Oncology		1,165,012			667,512
Notes payable - senior promissory, net of discount		7,498,333			3,399,383
Common stock warrant liability		7,099,842			340,636
Derivative liability		–			1,153,998
					–
Total Current Liabilities		19,397,124			8,581,290
Capital leases - long term		–			5,258
Total Liabilities		19,397,124			8,586,548
Stockholders' Deficit
Preferred stock, 5mm authorized, 2.5mm and 0 outstanding, respectively		2,500			–
Common stock, $.001 par value, 50mm authorized, 10.8mm and 10mm outstanding, respectively		10,833			10,000
Additional paid in capital		1,540,467			(1,200	)
Accumulated Deficit		(18,234,182	)		(5,479,949	)
Accumulated other comprehensive loss		(363,000	)		–
Total Stockholders' Deficit		(17,043,382	)		(5,471,149	)
Total Liabilities and Stockholders' Deficit	$	2,353,742		$	3,115,399

The accompanying notes are an integral part of these consolidated financial statements.

Helomics Holdings Corporation

Consolidated Statement of Operations and Other Comprehensive Loss

For the years ended December 31, 2018 and 2017

	2018			2017
	(As Restated)			(As Restated)
Revenue, net	$	400,778		$	1,578,995
Cost of goods sold		229,354			323,742
Gross margin		171,424			1,255,253
General & adminstrative expense		3,419,292			3,839,633
Operations expense		2,000,688			3,400,832
Sales & marketing expense		253			8,500
Total expense		5,420,233			7,248,965
Net loss on Operations		(5,248,809	)		(5,993,712	)
Amortization of debt issuance costs and debt discount		(3,083,544	)		(402,590	)
Unrealized (loss) gain common stock warrant liability		(3,614,950	)		151,567
Interest expense - notes payable and capital leases		(1,071,649	)		(17,011	)
Other income		269,052			–
Loss on convertible note		(4,333	)		–
Gain on settlement of note		–			215,516
Unrealized loss on derivative liability		–			(1,153,998	)
Net loss		(12,754,233	)		(7,200,228	)
Other comprehensive income
Unrealized loss on equity investment		(363,000	)		–
Comprehensive Loss	$	(13,117,233	)	$	(7,200,228	)

The accompanying notes are an integral part of these consolidated financial statements.

2

Helomics Holdings Corporation

Statement of Changes in Accumulated Deficit

	Preferred Stock Shares		Preferred Shares Amount		Common Stock Shares		Common Shares Amount		Additional Paid- In Capital			Accumulated Other Comprehensive Loss			Accumulated Deficit			Total
Balance @ 12/31/16 (as restated)		–		–		10,000,100	$	10,000	$	(1,200	)				$	1,720,279		$	1,729,079
Net Loss (As Restated)																(7,200,228	)		(7,200,228	)
Balance @ 12/31/17 (as restated)		–		–		10,000,100		10,000		(1,200	)					(5,479,949	)		(5,471,149	)
Issuance of Preferred Stock, 2,500,000 shares, $.001 per share		2,500,000	$	2,500					$	1,042,500									1,045,000
Issuance of Common Stock, 833,333 shares, $.001 per share						833,333		833		499,167									500,000
Unrealized loss on equity investment													(363,000	)					(363,000	)
Net Loss (As Restated)																(12,754,233	)		(12,754,233	)
Balance at 12/31/18 (as Restated)		2,500,000	$	2,500		10,833,433	$	10,833	$	1,540,467		$	(363,000	)	$	(18,234,182	)	$	(17,043,382	)

The accompanying notes are an integral part of these consolidated financial statements.          

3

Helomics Holding Corporation

Consolidated Statement of Cash Flows

For the years ended December 31, 2018 and 2017

	12/31/18			12/31/17
CASH FLOWS FROM OPERATING ACTIVITIES	(As Restated)			(As Restated)
Net Loss	$	(12,754,233	)	$	(7,200,228	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt issuance costs and debt discount		3,083,544			402,590
Unrealized loss (gain) on common stock warrant liability		3,614,950			(151,567	)
Depreciation and amortization		1,212,995			1,620,676
Loss on Convertible Note		4,333			–
Unrealized loss on derivative liability		–			1,153,998
Changes in operating assets and liabilities:
Receivables		186,659			(97,416	)
Prepaid Expenses & Other Assets		(957	)		282,360
Inventories		22,771			54,834
Accounts payable and accrued liabilities		694,758			505,915
Net Cash Used In Operating Activities		(3,935,180	)		(3,428,838	)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of Fixed Assets		(3,695	)		(63,095	)
Net Cash Used In Investing Activities		(3,695	)		(63,095	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from senior promissory notes		3,013,000			2,563,995
Proceeds for notes payable - Predictive Oncology		997,500			667,512
Payments on capital leases		(85,839	)		(89,026	)
Net Cash Provided by Financing Activities		3,924,661			3,142,481
Net Decrease In Cash And Cash Equivalents		(14,214	)		(349,452	)
CASH AND CASH EQUIVALENTS
Beginning of period		45,016			394,468
End of period	$	30,802		$	45,016
SUPPLEMENTAL DISCLOSURES OF CASH FLOWS INFORMATION
Cash paid during the period for interest	$	7,538		$	14,787
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES
Conversion of debt to common stock	$	500,000		$	–
Issuance of preferred stock	$	1,045,000		$	–
Conversion of derivative liability to notes payable	$	1,153,998		$	–

The accompanying notes are an integral part of these consolidated financial statements.

4

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - ORGANIZATION

A. Nature of Operations and Continuance of Operations

Helomics Holding Corporation (the “Company” or “Helomics”) was originally incorporated on November 15, 2016 in Delaware as Helomics Corporation. The Company commenced its operations on December 7, 2016, when Helomics Holding Corporation, through its wholly-owned subsidiary Helomics Intermediate Corporation, acquired all the outstanding shares of the Helomics Corporation. Helomics® is a personalized medicine company providing an actionable roadmap for patients and their oncologist to guide therapy and positively impact patient outcomes. The Company’s business model consists of three complementary pillars, all of which are currently revenue-generating and have growth strategies in place. The Company’s initial pillar is the Precision Oncology Insights business, which involves comprehensive tumor profiling, using the power of Artificial Intelligence and the Digital Clinical Health Insight Platform (D-CHIP), to provide a personalized oncology roadmap for patients and their oncologists. The Company’s second pillar offers boutique CRO (Contract Research Organization) services that leverage the Company’s TruTumor™, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to the Company’s client’s specific needs. The Company’s third pillar, the D-CHIP bioinformatics, is a proprietary Artificial Intelligence-powered bioinformatics engine that provides actionable insights from the rich patient data Helomics collects as part of its diagnostic business. Pharma and diagnostics companies use the D-CHIP to aid disease diagnosis or drive patient selection for clinical trials.

Helomics is specifically attentive toward oncology insights for six specific cancers (ovarian, breast, pancreatic, colon, lung and brain cancer), and the Company is building a bioinformatics database of artificial intelligence for those six cancers, providing actionable data that can facilitate the development of precision therapies.

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and was purchased by a new ownership group on December 7, 2016. The Company has experienced negative cash flows from operations since inception, and operations have been funded by debt and equity issuances. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not contain any adjustments to reflect the possible future effects of the recoverability or classification of assets or the amounts and classifications of liabilities that may result.

For the year ended December 31, 2018, the Company has continued to realize recurring losses from operations and thus a negative cash flow from operations. The Company completed its merger with a public company on April 4, 2019 for purposes of raising additional capital to fund operations going forward (see Note 14).

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies applied by management in the preparation of the accompanying financial statements follows:

5

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

A. PRINCIPLES OF CONSOLIDATION

The accompanying consolidated financial statements include the accounts of Helomics Holding Corporation, and its subsidiaries, Helomics Intermediate Corporation, and Helomics Corporation. All intercompany accounts and transactions have been eliminated in consolidation.

B. Accounting Policies and Estimates

The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial

statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. Advertising

Advertising costs are expensed as incurred. Advertising expenses were $253 and $8,500 for the years ended December 31, 2018 and 2017, respectively.

D. Research and Development

Research and development costs are charged to operations as incurred. There were no research and development costs incurred for the years ended December 31, 2018 and 2017, respectively.

E. Revenue Recognition

The Company currently recognizes revenue in accordance with ASC 605 - Revenue Recognition. The Company recognizes revenue when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. The precision diagnostics are recognized at gross revenue at time of final test and an uncollectible amount equal to the Company’s historical reimbursement average from Medicare and private payors insurance.

Effective January 1, 2019, the Company will adopt ASC 606 - Revenue from Contracts with Customers,

which amends the guidance for the recognition of revenue from contracts with customers for the transfer of goods and services, by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2019.

The results for the period beginning after January 1, 2019, will be presented in accordance with the new standard. Upon adoption, the Company will recognize revenue following the five-step model outlined in ASC 606. The Company’s CRO and D-CHIP revenue will be contract based as well as subscription based for D-CHIP in which revenue would be recognized on a monthly basis, equivalent to the term of the contract. For the year ended December 31, 2018, no such contracts have been entered into and therefore no cumulative adjustment was recorded as of January 1, 2019.

.

6

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

F. Cash Equivalents

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximate fair value. The Company at times maintains cash balances at financial institutions in excess of the amounts insured by the

Federal Deposit Insurance Corporation. The Company believes it has placed its cash with high credit quality financial institutions and does not believe it is exposed to any significant credit risk.

G. Fair Value Measurements

Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standards ASC 820 establishes a three-level fair value hierarchy that prioritizes information used in developing assumptions when pricing an asset or liability as follows:

Level 1 - Observable inputs such as quoted prices in active markets for identical assets and liabilities,

Level 2 - Inputs other than quoted prices in active markets, that are observable either directly or indirectly for similar assets and liabilities; and

Level 3 - Unobservable inputs where there is little or no market data, which requires the reporting entity to develop its own assumptions.

The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The carrying amounts of the Company’s cash, accounts receivable, accounts payable and the equity investment in Predictive Oncology Inc. (“Predictive”) (formerly Precision Therapeutics Inc.) approximated fair value as of December 31, 2018 due to their short-term nature (Level 1). The Company has common stock warrants, issued with notes payable, that are considered Level 3 in nature. The liability related to the common stock warrants is measured at the time of issuance and at fair market value on a quarterly basis using a Black Scholes pricing model (see note 8).

H. EQUITY INVESTMENT

In 2018 the Company sold a 20% equity position to Predictive in exchange for 1,100,000 shares of Predictive common stock (see Note 13). The Company records this asset on the balance sheet and is classified as an Equity investment. Management evaluates the investment quarterly and records an adjustment to the investment value based on the closing stock price at the end of each quarter and the gain or loss is recognized as unrealized in the other comprehensive income section of the statements.

On an annual basis the Company performs an impairment test of the asset due to events and changes in circumstances that indicates an impairment might have occurred.  There were no such impairment charges during 2018.

I. ReceIVABLES

Receivables are reported at the amount the Company expects to collect on balances outstanding.

7

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the

valuation allowance has not been material to the financial statements. The allowance for doubtful accounts was $1,320,170 and $0 as of December 31, 2018 and 2017, respectively.

J. Inventories

Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. Inventory balance is as follows:

	December 31,
	2018			2017
Lab Operating Supplies	$	27,790		$	72,022
Inventory Reserve		(10,282	)		(31,743	)
Total	$	17,508		$	40,279

K. Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:

	Years
Computer Equipment & Software		3
Leasehold Improvements		5
Laboratory Equipment		5-7
Furniture & Fixtures		3

The Company’s investment in fixed assets consists of the following:

	December 31,
	2018			2017
Computer Equipment & Software	$	462,876		$	459,181
Leasehold Improvements		56,154			56,154
Laboratory Equipment		3,432,523			3,432,523
Furniture & Fixtures		194,710			194,710
Total		4,146,263			4,142,568
Less: Accumulated Depreciation		(2,942,691	)		(1,743,724	)
Total Fixed Assets, net	$	1,203,572		$	2,398,844

Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations.

8

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Maintenance and repairs are charged to operations as incurred. Depreciation expense was $1,198,967 and $1,606,648 for the years ended December 31, 2018 and 2017, respectively.

L. Intangible Assets

Intangible assets consist of trademarks and patent costs. Amortization expense was $14,028 for the years ended December 31, 2018 and 2017, respectively. The assets are amortized over eighteen years and are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified.

The remaining amortization expense for the intangible assets consists of the following:

Year Ended	Amount
2019	$	14,028
2020		14,028
2021		14,028
2022		14,028
2023		14,028
Thereafter		90,635
Total	$	160,775

The Company reviews identifiable intangible assets for impairment in accordance with ASC 350 - Intangibles - Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. The Company’s intangible assets are currently solely the costs of obtaining trademarks from the Company’s acquisition of Helomics. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management’s best estimate of the related risks and return at the time the impairment assessment is made. Based on the Company's evaluation, no impairment expense has been recognized for the years ended December 31, 2018 and 2017.

M. Income Taxes

The Company accounts for income taxes in accordance with ASC 740 - Income Taxes (ASC 740). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.

9

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.

Tax years 1999 through 2018 remain open to examination by federal and state tax authorities due to the carryforward of unutilized net operating losses (NOLs).

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (Tax Reform Act) was signed into law, making significant changes to the Internal Revenue Code. Changes include a reduction in the corporate tax rates, changes to operating loss carry forwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduces the U.S. corporate income tax rates from 34% to 21%. As a result of the enacted law, the Company was required to revalue its deferred tax assets and liabilities at the new enacted rate.

N. Patents and Intellectual Property

All Patents and Intellectual Property of ChemoFx® in use by the Company are currently owned by Healthcare Royalty Partners (former owners) and are being used by the Company in accordance with the Merger Agreement between Helomics and HealthCare Royalty Partners. The Company agreed to a term sheet for a nonexclusive license agreement on the patented ChemoFx technology. Terms were for an 8% royalty on net sales of ChemoFx®. As of the date of this report, the license agreement has not been finalized, and no accrued royalty has been recognized.

O. Risks and Uncertainties

The Company is subject to risks common to companies in the clinical diagnostic and service industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

P. RecentLY ISSUED Accounting PRONOUNCEMENTS

In May 2014, the FASB issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB ASC, Topic 606, and has since amended the standard with ASU 2015-14, “Revenue from Contracts with Customers: Deferral of the Effective Date” (ASU 2016-08), “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net)” (ASU 2016-10), “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing” (ASU 2016-12), “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients” (ASU 2017-13). These new standards provide a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and requires enhanced disclosures.

10

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The amendments are effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early application is permitted. The FASB will allow two adoption methods, the full retrospective and modified retrospective approaches. The Company will implement the modified retrospective method which will be effective for the Company for all contracts with customers’ existing as of December 31, 2018. This standard will impact the Company’s CRO and D-CHIP business units as revenue from these units are generally contract based, are executed over a period of time and in some cases have multiple phases and/or milestones. Implementation of the standard in January 2019, using the modified retrospective approach, is not expected to have a material effect on revenue, gross margin or operating income.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (ASU 2016-01).

The standard changes how entities measure certain equity investments and present changes in the fair value of financial liabilities measured under the fair value option that are attributable to their own credit. Under the new guidance, entities will be required to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income unless the investments qualify for the new practicability exception. The standard is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. The Company has adopted this guidance in January 2019 and earnings on the equity investment will be recognized in net loss and no longer be recorded in other comprehensive income.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842 (ASU 2016-02), which requires lessees to put most leases on their balance sheets but recognize the expenses on their income statements in a manner similar to current practice. The standard states that a lessee would recognize a lease liability for the obligation to make lease payments and a right-to-use asset for the right to use the underlying asset for the lease term. The standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the timing of its adoption and the impact that the updated standard will have on its financial statements.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to address diversity in how certain cash receipts and cash payments are presented and classified in the statements of cash flows. The amendments are effective for non-public business entities for fiscal years beginning after December 15, 2018. The amendments should be applied using a retrospective transition method to each period presented. If retrospective application is

impractical for some of the issues addressed by the update, the amendments for those issues would be applied prospectively as of the earliest date practicable. Early adoption is permitted, including adoption in an interim period. The Company has adopted ASU 2016-15 in January 2019 and it did not have a material impact on its financial statements.

Q. RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS

In July 2017, FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.

11

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

The amendments in this update are intended to simplify the accounting for certain equity-linked financial instruments and embedded features with down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under the new guidance, a down round feature will no longer need to be considered when determining whether certain financial instruments or embedded features should be classified as liabilities or equity instruments. That is, a down round feature will no longer preclude equity classification when assessing whether an instrument or embedded feature is indexed to an entity's own stock. In addition, the amendments clarify existing disclosure requirements for equity-classified instruments. These amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2019, with early adoption permitted. The Company early adopted the applicable amendments in 2017 on a retrospective basis, which did not impact the Company’s financial statements.

The Company reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to its business or that no material effect is expected on its financial position and results of its operations.

R. IMPAIRMENT

As a result of continued operating losses and cash flow deficiencies, the Company completed certain tests for the recoverability of long-lived assets held and used at the asset group level. Assessing the recoverability of long-lived assets held and used requires significant judgments and estimates by management. The Company will be required to conduct additional testing for the recoverability of long-lived assets held and used to the extent that a triggering event requiring such testing is identified in a future period.

The Company reviews its long-lived assets and certain identifiable intangibles for impairment whenever changes in circumstances indicate that the carrying amount of an asset might not be fully recoverable.  The analysis of the recoverability utilizes undiscounted future cash flows.  The measurement of loss, if any, is calculated as the amount by which the carrying amount of the assets exceeds the estimated fair value as determined by comparable market transactions.

On an annual basis the Company performs an impairment test of certain long-lived assets due to events and changes in circumstances that indicates an impairment might have occurred.  There were no such impairment charges during 2018 or 2017.

NOTE 3 – RESTATEMENT

Subsequent to the issuance of the consolidated financial statements for the years ended December 31, 2018 and 2017, the Company discovered an error related to the accounting for the common stock warrants issued with convertible and senior promissory notes. In addition, there were additional warrants issued upon conversion of the convertible notes (see Note 4) that were previously not accounted for at issuance.

As previously stated within the financial statements the warrants were recognized as an equity instrument and using a Black Scholes pricing model the value of the warrants was recorded in additional paid in capital along with a debt discount to the notes. After issuance of the financial statements the Company determined that the warrants carried a cash value option and with such the proper treatment should have been to record the warrants as a liability as opposed to equity. In addition, the warrants that were issued to the placement agent should have been recorded at fair value as an asset to prepaid debt issuance costs.

12

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – RESTATEMENT (Continued)

Additionally, there were 3,475,000 warrants that were issued upon auto conversion of the notes executed prior to 2018 that the Company had not previously recognized. The Company also adjusted the option value pricing on the Black Scholes model to reflect the value of the warrants on the day of issuance compared to previously being recorded at a value based on the month end.

The Company is required to record a fair value adjustment on the warrants and has done so using a Black Scholes pricing model. As a result of this change in treatment, the Company recognized additional assets and liabilities on the balance sheet as well as an adjustment to equity to correct the previously recognized treatment. On the statement of operations there was additional expense recorded in relation to the amortization of the debt issuance costs and debt discount as well as the fair value adjustments.

As a result of the restatement, the Company realized an increase in assets of $12,921 and $24,591 as of December 31, 2018, and 2017, respectively, due to the recording of debt issuance costs and the amortization of those costs. Current liabilities increased by $7,076,632 and $278,024 as of December 31, 2018 and 2017, respectively due to the recognition of the warrants as a liability compared to equity. Subsequently the additional paid in capital decreased by $3,714,295 and $2,410 as of December 31, 2018 and 2017, respectively due to the reclassification of the warrants from equity to liability. Amortization expense increased by $3,098,393 and $268,034 for the years ending December 31, 2018 and 2017, respectively.

Net loss also increased by $3,098,393 and $251,023 for the years ending December 31, 2018 and 2017, respectively and total stockholders’ deficit increased by $7,063,711 and $253,433 as of December 31, 2018 and 2017, respectively.

The following sets forth the previously reported and restated amounts of selected items within the consolidated balance sheets as of December 31, 2018 and 2017, as well as the consolidated statements of operations for the years ended December 31, 2018 and 2017:

2018	As Previously Reported		As Restated		change
Prepaid expenses	$	8,524	$	21,445	$	12,921
Current assets		294,474		307,395		12,921
Total assets		2,340,821		2,353,742		12,921
Notes payable - senior promissory, net of discount		7,521,543		7,498,333		(23,210	)
Common stock warrant liability		-		7,099,842		7,099,842
Current liabilities		12,320,492		19,397,124		7,076,632
Total liabilities		12,320,492		19,397,124		7,076,632
Additional paid in capital		5,254,762		1,540,467		(3,714,295	)
Accumulated deficit		14,884,766		18,234,182		3,349,416
Total stockholders deficit		9,979,671		17,043,382		7,063,711
Amortization of debt issuance and debt discount		3,600,102		3,083,544		(516,558	)
Unrealized loss common stock warrant liability		-		3,614,950		3,614,950
Net loss		9,655,840		12,754,233		3,098,393

13

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 – RESTATEMENT (Continued)

2017	As Previously Reported		As Restated			change
Prepaid expenses	$	7,567	$	32,158		$	24,591
Current assets		517,161		541,752			24,591
Total sssets		3,090,808		3,115,399			24,591
Notes payable - senior promissory, net of discount		3,461,995		3,399,383			(62,612	)
Common stock warrant liability		-		340,636			340,636
Current liabilities		8,303,266		8,581,290			278,024
Total liabilities		8,308,524		8,586,548			278,024
Additional paid in capital		1,210		(1,200	)		(2,410	)
Accumulated deficit		5,228,926		5,479,949			251,023
Total stockholders deficit		5,217,716		5,471,149			253,433
General & administrative expense		3,854,926		3,839,633			(15,293	)
Operations expense		3,402,550		3,400,832			(1,718	)
Amortization of debt issuance and debt discount		2,224		402,590			400,366
Unrealized gain common stock warrant liability		-		(151,567	)		(151,567	)
Net loss		6,949,205		7,200,228			251,023
Net Cash used in operating activities		3,431,061		3,428,838			(2,223	)
Net Cash Provided by financing activities		3,081,609		3,142,480			60,871

NOTE 4 – SENIOR PROMISSORY NOTES

Commencing on December 7, 2016 and through September 19, 2017, the Company, through a series of transactions with various investors, raised $3,461,995 through the sale of convertible promissory notes with various maturity dates that could be extended by the Company with an automatic conversion feature in the

event of qualified financing. The Company issued warrants equal to 1% of the offering price to note holders to purchase shares of common stock at an exercise price of $1.00 per share.

In connection with the offering, the Company paid the placement agent a placement agent fee of 8% of the gross proceeds received in the offering, 5% net payout of which was paid to the placement agent's brokers in connection with the offering. Additionally, the Company issued placement agent warrants to purchase 20% of the aggregate number of common stock purchase warrants sold in the offering, with an exercise price of $0.01 per share.

The notes were subject to an automatic conversion feature whereby in the event of a qualified financing, the notes will be convertible at 75% of the aggregate purchase consideration paid by investors in the qualified financing. Due to the terms of the convertible notes payable, the Company determined the notes contained an embedded derivative which was required to be bifurcated and valued at the time of issuance.

The Company determined the derivative had no value at the time of issuance of the notes; however, as of December 31, 2017 the Company determined it was probable that a qualified financing event would occur, which resulted in recognition of a derivative liability of $1,153,998 as well as a loss on derivative instrument on the consolidated statement of operations for the year ended December 31, 2017. The conversion feature resulted in an increase in value of the notes from $3,461,995 to a total liability of $4,615,993, including the derivative liability of $1,153,998 at December 31, 2017.

14

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 – SENIOR PROMISSORY NOTES (Continued)

The terms of the convertible promissory notes for the year ended December 31, 2017, prior to conversion, included maturity dates ranging from June 30, 2018 to September 20, 2018 and bore no interest. Upon conversion in 2018 the term of the notes changed to a maturity date of January 16, 2019 and the interest on the notes matched the 15% interest on the senior promissory notes issued in 2018.

In January 2018, the Company executed a Subscription Agreement to bring additional operating capital into the company in the form of 15% senior promissory notes. The private offering was up to $3,000,000 and 6,000,000 warrants to purchase shares of the Company’s common stock. The warrants carry an exercise price of $1.00. Through a series of transactions with various investors from January through October 2018, the Company raised $3,013,000 through the sale of senior promissory notes. The issuance of these senior notes triggered a qualified financing event and thus the convertible promissory notes issued in 2016 and 2017 were converted into the senior promissory notes.

After the Company closed on the qualified financing, triggering the auto conversion of the 2016 and 2017 notes, the total liability on promissory notes totaled $7,633,326. In addition to the original 3,461,995 warrants issued with the convertible notes, the Company was required to issue an additional 9,279,672 common stock warrants. The majority of the noteholders have agreed to convert their notes into Predictive common stock upon close of the acquisition (see Note 14).

The Company recorded debt issuance costs of $122,927 and $140,787 for the years ending December 31, 2018 and 2017, respectively, as well as a debt discount of $3,021,329 and $349,007 for the same periods. The value of these warrants was determined using a Black Scholes pricing model and both amounts are amortized over the term of the notes. Amortization expense of debt issuance costs and debt discount totaled $3,083,544 and $402,590 for the years ended December 31, 2018 and 2017, respectively.

At December 31, 2018 and 2017 outstanding senior promissory notes consisted of:

	December 31,
	2018			2017
Senior Promissory Notes	$	7,633,326		$	3,461,995
Debt Discounts - Warrants		(134,993	)		(62,612	)
	$	7,498,333		$	3,399,383

NOTE 5 - NOTES PAYABLE – PREDICTIVE ONCOLOGY

The Company has received cash advances from in Predictive totaling $1,665,012 which is collateralized by equipment owned by the Company in excess of $700,000. These secured promissory notes bear interest of 8% per annum. In January 2018, $500,000 of these notes were converted into common stock resulting in a total note payable of $1,165,012 as of December 31, 2018. Upon completion of the acquisition, (see note 14) all remaining balances on the notes were eliminated.

15

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - NOTES PAYABLE – HEALTHCARE ROYALTY PARTNERS

At December 31, 2016, the Company carried a note balance of $1,673,513 with Healthcare Royalty Partners from the acquisition transaction in 2016. On October 18, 2017, the Company agreed to assume accounts payables that originally were retained by Health Care Royalty Partners, in exchange for forgiveness of the remaining balance due. As a result, the Company recognized additional liabilities of $615,108, and recognized a gain of $215,516 for the difference in the additional amount assumed, and the open principal balance of the note.

NOTE 7 - EQUITY

On December 6, 2016, the Company amended its Certificate of Incorporation to increase the authorized shares of its common stock, $.001 par value, to 50,0000,000 shares from 1,000,000 shares and increase the authorized shares of its preferred stock, $.001 par value, to 5,000,000 shares from 100,000 shares.

Common Stock

At December 31, 2018 and 2017, the Company had issued and outstanding 10,833,433 and 10,000,100 shares of its common stock, respectively. See note 13 for issuance of additional common stock in connection with the conversion of $500,000 in notes payable to Predictive.

Preferred Stock

At December 31, 2018 and 2017, the Company had issued and outstanding 2,500,000 and 0 shares, respectively. See note 13 for issuance of preferred stock to Predictive in connection with the stock exchange agreement that was executed in January 2018. The terms of the preferred stock are described below:

Voting

The preferred stockholders are entitled to vote, together with the holders of common stock as one class, on all matters to which holders of common stock shall be entitled to vote, in the same manner and with the same effect as the common stockholders.

Dividends

The holders of the preferred stock shall be entitled to receive dividends, when, as, and if declared by the board of directors, ratably with any declaration or payment of any dividend on common stock. To date there have been no dividends declared or paid by the Company.

Liquidation

The holders of the preferred stock shall be entitled to receive, before and in preference to, any distribution of any assets of the Company to the holders of common stock, an amount equal to $0.001 per share, plus any declared but unpaid dividends.

NOTE 8 - STOCK WARRANTS

Common Stock warrants issued with the convertible and senior promissory notes carry a warrant liability feature which requires the Company to record a fair market value adjustment of the liability. The Company uses a Black Scholes Model for valuing the warrants.

At time of issuance, a liability was recorded for the common stock warrants with a corresponding increase to prepaid debt issuance costs as well as the debt discount. The debt issuance costs and debt discount are amortized over the term of the notes. On a quarterly basis, the fair market value of the warrants is calculated by the Company and any change in value is recorded accordingly.

16

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 - STOCK WARRANTS (Continued)

A fair market value adjustment as of December 31, 2018 resulted in an additional liability of $3,614,950 compared to a reduction in liability of $151,567 as of December 31, 2017. The total liability for all common stock warrants issued by the Company were valued at $7,099,842 and $340,636 as of December 31, 2018 and 2017, respectively.

Stock warrant transactions for the years ended December 31, 2018 and 2017 were as follows:

	Warrants		Exercise Price
Warrants Outstanding & exercisable
at December 31, 2016		1,077,600	$	.01-1.00
Granted during the period:
Investor warrants		2,564,395	$	1.00
Placement Agent warrants		512,800		0.01
Warrants Outstanding & exercisable
at December 31, 2017		4,154,795	$	.01-1.00
Granted during the period:
Investor warrants		15,279,272	$	1.00
Placement Agent warrants		302,600		0.01
Warrants Outstanding & exercisable
at December 31, 2018		19,736,667

	# of Shares under
Exercise Price	Warrants
$0.01		995,000
$1.00		18,741,667
Total Warrants		19,736,667

The common stock warrants have an expiration date of five years from the issuance date and an exercise price of $1.00. The common stock warrants issued to the placement agent have an expiration date of five years from the issuance date and an exercise price of $0.01.

The fair market value of the Company’s warrants is as follows:

Ending Balance at December 31, 2016	$	120,725
Warrants issued during the period		371,478
Fair value adjustment		(151,567	)
Ending Balance at December 31, 2017		340,636
Warrants issued during the period		3,144,256
Fair value adjustment		3,614,950
Ending Balance at December 31, 2018	$	7,099,842

17

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 9 - INCOME TAXES

The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.

Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted December 22, 2017.

Effective January 1, 2018, the Tax Reform Act reduced corporate income tax rates from 34% to 21%. Other changes effect operating loss carryforwards and carrybacks, as well as a repeal of the corporate alternative minimum tax. As a result of the Tax Reform Act, deferred tax assets and liabilities were re-measured to account for the lower tax rates.

There was no income tax impact from the re-measurement due to the 100% valuation allowance on the Company’s deferred tax assets. There is no federal or state income tax provision in the accompanying statements of operations due to the cumulative operating losses incurred and 100% valuation allowance for the deferred tax assets.

During June 2013 and December 2016, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code, which could potentially limit the amount of the Company’s net operating loss (NOLs) carryforwards that may be utilized on an annual basis to offset taxable income in future periods. In addition, the Company may have experienced additional ownership changes further limiting the NOL carry-forwards. Consequently, the limitations, if any, could result in the expiration of the Company’s loss carryforwards before they can be utilized.

The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.

At December 31, 2018 and 2017, the Company had approximately $237,737,000 and $236,021,000 of gross NOLs to reduce future federal taxable income, subject to the Section 382 limitation described above. Approximately $2,556,000 of federal NOL expired at December 31, 2018. Additional federal NOL will expire annually if unused. The Company also has state NOLs which have begun to expire at December 31, 2018 and will continue to expire annually if unused.

The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At December 31, 2018 and 2017, the federal and state valuation allowances were $66,674,000 and $62,900,000, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change.

Management evaluated the Company’s tax positions considering many factors, including past experience and complex judgments about future events and concluded that the Company had taken no uncertain tax positions at December 31, 2018 and 2017 that require adjustment to the financial statements. The Company does not anticipate significant changes in its uncertain tax positions over the next twelve months. It is the Company’s practice to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

18

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10 - LEASE OBLIGATIONS

The Company’s corporate offices are located at 91 43^rd Street Pittsburgh, PA. On October 17, 2017, the Company signed a second amendment to its lease last amended on February 28, 2016. The lease, as amended, has a three-year term effective February 1, 2018, ending January 31, 2021.

The Company leases 17,417 square feet at this location, of which approximately 1,000 square feet are used for office space and 16,417 square feet is used for laboratory operations. The Company expects that this space will be adequate for its current office and laboratory needs. Rent expense was $414,261 and $588,445 for the years ended December 31, 2018 and 2017, respectively.

The Company’s remaining rent obligation for the next three years is as follows:

Year Ended	Amount
2019	$	393,450
2020		393,450
2021		32,788
	$	819,688

NOTE 11 - CAPITAL LEASE OBLIGATIONS

In December 2017, the Company financed the purchase of equipment with a value of $126,190, through a capital lease arrangement of $63,095 and from a note from Predictive of $63,095.

The value of the equipment is included in the laboratory equipment within the fixed assets on the consolidated balance sheet.

Future minimum capital lease payments as of December 31, 2018 were comprised of the following:

2019	$	5,488
Less: Amounts representing interest		(230	)
	$	5,258

NOTE 12 - RETIREMENT SAVINGS PLANS

The Company has a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In 2018 and 2017, the Company matched 25%, of the employees’ contribution up to 6.0% of their earnings. The employer contribution was $19,204 and $21,838 for the years ended December 31, 2018 and 2017, respectively. There were no discretionary contributions to the plan in 2018 and 2017.

NOTE 13 - SALE OF PREFERRED STOCK

On January 12, 2018, Helomics Holding Corporation issued 2,500,000 shares of its Series A Preferred Stock to Predictive in exchange for 1,100,000 shares of Predictive common stock, with a market value of $.95 per share. The shares of Helomics preferred stock are convertible into 20% of the outstanding capital stock of Helomics. The 1,100,000 shares of Predictive common stock are being held in escrow for Helomics pursuant to an escrow agreement under which the shares will be released following a determination that

19

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13 - SALE OF PREFERRED STOCK (Continued)

Helomics’ revenues in any 12-month period have been equal to or greater than $8,000,000. Per the agreement there is no maturity date on the escrow agreement and the Company does not lose the right to the shares in escrow unless an agreement is reached to terminate the escrow agreement or the share exchange agreement.

The Company does not have the ability to trade these shares until the shares are released from escrow. The asset for this transaction is recorded on the balance sheet as equity investment. The Company recognized an unrealized loss in other comprehensive income on the securities of $363,000, reflective of the stock price of $0.62 at December 31, 2018. In addition, on February 27, 2018, Predictive converted a principal amount of $500,000 in secured notes into 833,333 shares of Helomics common stock.

The Helomics shares held by Predictive, in the aggregate, represent 25% of the outstanding capital stock of Helomics on an as-converted basis as of December 31, 2018.

NOTE 14 - ACQUISITION

On June 28, 2018, the Company entered into a definitive merger agreement with Predictive to acquire the remaining stock. Under the terms of the deal, upon completion of the merger, all outstanding shares of Helomics stock not already held by Predictive will be converted into the right to receive a proportionate share of 4,000,000 shares of newly issued Predictive common stock and 3,500,000 shares of newly issued Predictive preferred stock, in addition to the 1,100,000 Predictive shares already issued to Helomics for Predictive’s initial 20% ownership in Helomics.

The merger is conditional on at least 75% of Helomics’ $7,600,000 in outstanding promissory notes being exchanged for additional shares of Predictive common stock at $1.00 per share. In addition, the note holders were offered additional warrants in exchange for converting the debt at merger close. The note holders from the 2018 capital raise were offered an additional 5,000,000 warrants to convert their notes to Predictive stock at close of merger. If all note holders exercised the option to convert, the total outstanding investor warrants at the time of merger would total 23,741,772. These Helomics warrants will be exchanged for warrants to purchase Predictive common stock, at a ratio of 0.6 Predictive warrants for each Helomics warrant. The acquisition was completed on April 4, 2019 (see note 17).

NOTE 15 - COMMITMENTS AND CONTINGENCIES

The Company has several legal claims brought against it in 2017 and 2018 from vendors seeking payment on past due invoices totaling $134,811. All claims were either settled with agreed upon payment plans or settlements are being negotiated with the vendors whereby all outstanding amounts will be paid in full, all of which the liability is captured in accounts payable. The Company expects no litigation in these matters and therefore believes there is no additional financial exposure, other than amounts already recorded within accounts payable. The Company does not have any other commitments or contingencies as of December 31, 2018.

20

HELOMICS HOLDING CORPORATION AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 16 – RELATED PARTY TRANSACTIONS

During the period ended December 31, 2018, the Company’s officers advanced to the Company an amount of $42,253 by way of a loan, for purposes of processing payments to Company vendors. As of December 31, 2018, the Company was obligated to the officers, for an unsecured, non-interest-bearing demand loan with a balance of $42,253. This note is recorded within accounts payable liability on the balance sheet.

NOTE 17 – SUBSEQUENT EVENTS

Management has evaluated subsequent events through May 13, 2019 and September 25, 2019, the dates on which the consolidated financial statements were available to be issued and restated, respectively.

A. NOTES PAYABLE - PREDICTIVE ONCOLOGY

Between January and April 2019, the Company received advances totaling $975,000 in the form of promissory notes from Predictive. The promissory notes bear interest of 8% per annum. At the close of acquisition by Predictive on April 4, 2019 the notes and interest were eliminated.

B. ACQUISITION

On April 4, 2019, the acquisition of Helomics by Predictive was completed. (i) Upon completion of the acquisition Predictive acquired all outstanding shares of Helomics stock not already held and were converted into the right to receive a proportionate share of 4,000,000 shares of Predictive common stock and 3,500,000 shares of Series D Convertible Preferred Stock. The fair value of these shares on the date of issuance was $5,612,250; (ii) Predictive forgave notes and interest due from Helomics relating to previous cash advances equaling $2,210,381; (iii) Predictive eliminated debt of $7,633,326 owed by Helomics to noteholders by issuing 8,637,323 shares of common stock to the noteholders, the value of the shares was $6,463,309; (iv) At date of merger Helomics had 18,741,667 warrants issued to noteholders and agreed to issue an additional 5,000,000 warrants. Predictive issued 14,245,063 of Predictive warrants in exchange for warrants to purchase 23,741,772 shares of Helomics common stock to the Helomics noteholders agreeing to extinguish or extend their notes. An additional 597,000 warrants were exchanged for warrants held by other parties; the total consideration of all the exchanged warrants was valued by using the Black Scholes method and equaled $6,261,591; and, (v) Predictive’s acquisition of Helomics was a business combination achieved in stages, the initial 25% purchase of Helomics in 2018 was required to be revalued at current fair value on the Acquisition Date.

20